indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
corporate

Fermenta Biotech Limited merges with its holding company, DIL Limited – synergies for accelerated growth

IMT News Desk
Mumbai : DIL Ltd. (BSE: DIL) announced the merger of its subsidiary, Fermenta Biotech Ltd. (FBL), one of the leading Vitamin D3 manufacturers globally, with DIL. Pursuant to applications made by DIL and FBL to the National Company Law Tribunal, Mumbai (NCLT) for approval of the scheme of amalgamation of FBL with DIL, the NCLT has approved the said merger vide its Order dated 19th September, 2019. The order of the NCLT has been uploaded on its website www.nclt.gov.in on 25th September, 2019. The intimation to BSE Limited regarding the Order has also been done subsequently on  25th September, 2019. The copy of the said intimation is also available on www.dil.net. As per the approved scheme of amalgamation, post merger, the name of the combined entity will be ‘FERMENTA BIOTECH LIMITED’. The merger took place purely in the interest of business growth, in order to combine resources of both companies, effectively manage operations, focus on business priorities and maximisation of stakeholders’ benefits. The merger is also anticipated to bring greater efficiency in cash management and unfettered access to cash flows generated by the combined business. Further, cost savings are expected to flow from more focused operational efforts, standardization of business processes and rationalization of administrative expenses.   Commenting on the development, Mr. Krishna Datla, Managing Director said, “The amalgamation represents a major milestone for us in carrying forward our legacy of over six decades. It is expected to combine the synergies of both companies that will enhance our operational efficiencies. Further, it will enable us to focus our resources to bring in value-added formats in the nutraceutical ingredients space in order to diversify our product portfolio.” FBL caters to over 300 customers across 50 countries, with a worldwide distribution network across applications such as pharmaceuticals, food, dietary and nutritional supplements, feed, veterinary and rodenticides. Apart from Vitamin D, FBL is a pioneer in the enzyme technologies space, offering enzymes for antibiotic synthesis and industrial applications.  Moving forward, the combined entity shall augment its focus on the nutrition sector, by means of organic and inorganic growth opportunities.

Recommended

Morepen Board proposes dividend after 23 years

Dr Reddy’s posts consolidated revenue of Rs 85.1 bn in Q4 Fy25

Hester Biosciences posts consolidated net profit of Rs 28.83 Cr in FY25

Morepen targets Rs 1,000 Cr finished dosages biz within next five years

Natco challenges Roche’s Rs 6.2 lakh drug with Rs 15,900 alternative—but legal firestorm puts launch on hold

Granules India acquires Swiss-based Senn Chemicals

OneSource Secures approval from Brazil for its flagship facility

Biocon Biologics bags US FDA approval for Jobevne to treat cancer

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions